Scot Michael Elder - 01 Oct 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: *Chief Legal & Compliance Officer, Corporate Secretary
Issuer ticker: TMCI
Reported as of: 01 Oct 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Oct 2022, 18:00:56 UTC
Prior SEC filing: 14 Mar 2022
Next SEC filing: 02 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for Scot Elder

Key filing fact

Scot Michael Elder filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 04 Oct 2022.

Key facts

This page summarizes Scot Michael Elder's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Oct 2022, 18:00.

Change

Previous filing in this sequence was filed on 14 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Award

Transaction value: $0
Shares: +6,600
Change %: +51%
Price: $0.000000
Shares after: 19,475
Date: 01 Oct 2022
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TMCI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +47,000
Change %
Price: $0.000000
Shares after: 47,000
Date: 01 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,000
Exercise price: $22.07
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on October 1, 2023 with the last installment on October 1, 2026 subject to Reporting Person's providing continued service to Issuer through each vesting date.

Footnote F2

Includes 19,475 RSUs.

Footnote F3

The stock option will vest in equal annual installments over 4 years, commencing on October 1, 2023 with the last installment on October 1, 2026 subject to Reporting Person's providing continued service to Issuer through each vesting date.

SEC remarks

*Chief Legal & Compliance Officer, Corporate Secretary